Get Premium to unlock powerful stock data
XSWX:REGN (USA)  
Regeneron Pharmaceuticals Inc logo

Regeneron Pharmaceuticals Inc

CHF 303.92 (0%) Jun 14
P/E:
8.53
P/B:
3.31
Market Cap:
CHF 33.26B ($ 34.67B)
Enterprise V:
CHF 29.08B ($ 62.93B)
Volume:
-
Avg Vol (2M):
-
Also Trade In:
Volume:
-
Market Cap CHF:
33.26B
Market Cap $:
34.67B
PE Ratio:
8.53
Avg Vol (2-Month):
-
Enterprise Value CHF:
29.08B
Enterprise Value $:
62.93B
PB Ratio:
3.31
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download Tutorials

Business Description

Regeneron Pharmaceuticals Inc
NAICS : 325412 SIC : 2834
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Description
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently.
Name Current Vs Industry Vs History
Cash-To-Debt 2.61
Equity-to-Asset 0.76
Debt-to-Equity 0.14
Debt-to-EBITDA 0.29
Interest Coverage 162
Piotroski F-Score 7/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 9.52
Distress
Grey
Safe
Beneish M-Score -1.96
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
6-1 Month Momentum % -18.57
12-1 Month Momentum % -5.1

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.76
Quick Ratio 4.09
Cash Ratio 2.34
Days Inventory 292.22
Days Sales Outstanding 121.6
Days Payable 71.44

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio 0.1

Financials (Next Earnings Date:2022-08-05 Est.)

XSWX:REGN's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil CHF) 15,167.254
EPS (TTM) (CHF) 0
Beta 0
Volatility % 33.89
14-Day RSI 0
14-Day ATR (CHF) 0
20-Day SMA (CHF) 0
12-1 Month Momentum % -5.1
52-Week Range (CHF) 298.16 - 434.6
Shares Outstanding (Mil) 109.64

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 7
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Regeneron Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data